Below is a representative list of posters and podium presentations that have been presented at scientific conferences and relate to Ambit's proprietary research and development programs, or have resulted from collaborations with other biotechnology or pharmaceutical companies, or academic collaborators. Most contain links to copies of the poster or presentation.
A Phase II, Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations: Interim Results (presentation). Cortes, Jorge, et al. European Hematology Association 2011 Annual Meeting
Saturation Mutagenesis of FLT3-ITD: AC220-Resistance-Conferring Kinase Domain Mutations are Restricted to a Limited Number of Residues and are Cross-Resistant to Sorafenib in vitro (presentation). Smith, C.C. et al. American Association of Cancer Research 2011 Annual Meeting
Inhibition of FLT3 Signaling Both In Vitro and In Vivo by AC220, a Second Generation Potent and Selective FLT3 Inhibitor (poster). Gunawardane, R.N. et al. American Association of Cancer Research 2010 Annual Meeting
AC430, a potent JAK2 inhibitor, provides protection in multiple inflammatory and autoimmune disease models (poster). Belli, Barbara et al. American College of Rheumatology 2010 Annual Meeting
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human Phase 1 AML Study (presentation). Trikha, Mohit et al. Targeted Anticancer Therapies 2010 Annual Meeting
AC220, a uniquely potent and selective FLT3 inhibitor, provides sustained protection in a FLT3 ITD driven model of acute myeloid leukemia (poster). Belli, Barbara et al. American Association of Cancer Research 2009 Annual Meeting
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, In a First-In-Human Phase 1 AML Study (presentation). Cortes, Jorge et al. American Society of Hematology 2009 Annual Meeting
Characterization of the Biochemical and Cellular Activity of the Second-Generation FLT-3 Inhibitor AC220 (poster). Zarrinkar, P.P. et al. American Association of Cancer Research 2009 Annual Meeting
Efficient Lead Discovery by High Throughput Kinase Profiling (presentation). Zarrinkar, P.P. American Association of Cancer Research 2009 Annual Meeting
AC220, a uniquely potent and selective FLT3 inhibitor, enhances the cytotoxic effects of chemotherapeutic agents in cell culture and in mouse tumor xenografts (poster). Belli, Barbara et al. American Society of Hematology 2009 Annual Meeting
AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration (poster). Brigham, Daniel et al. American Society of Hematology 2009 Annual Meeting
Broad Activity of AC480, a pan-HER Inhibitor, Against HER1 and HER2 Expressing Tumor Cells (poster). Gunawardane, R.N. et al. American Association of Cancer Research 2008 Annual Meeting
AC220 Clinical Pharmacokinetics and Ex-Vivo FLT-3 Phosphorylation Inhibition Using the Plasma Inhibition Assay (poster). James, Joyce et al. American Society of Hematology 2008 Annual Meeting
AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor (presentation). Zarrinkar, P.P. et al. American Society of Hematology 2008 Annual Meeting
Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor (presentation). Cortes, Jorge et al. American Society of Hematology 2008 Annual Meeting
Development of potent and selective inhibitors of FLT-3 kinase with good pharmacokinetic profiles (poster). Patel, H.K. et al. American Association of Cancer Research 2007 Annual Meeting
AC220 Preclinical Profile and Early Human Experience in Relapsed or Refractory Acute Myeloid Leukemia (poster). Cortes, Jorge et al. American Society of Hematology 2007 Annual Meeting
Development of potent and selective inhibitors of FLT-3 kinase with good pharmacokinetic profiles (poster). Grotzfeld, R.M. et al. American Cancer Society 2006 Annual Meeting
Preclinical Anti-Tumor Efficacy of BMS-599626 (AC480), a Potent and Highly Selective Inhibitor of HER1 (EGFR) and HER2 Kinases (poster). Wong, T. W. et al. American Society of Clinical Oncology 2005 Annual Meeting
Preclinical Anti-Tumor Efficacy of BMS-599626 (AC480), a Potent and Highly Selective Inhibitor of HER1 (EGFR) and HER2 Kinases (presentation). Wong, T.W. et al. American Association of Cancer Research 2005 Annual Meeting
The pan-HER inhibitor BMS-599626 (AC480): biological effects, pharmacokinetic profile, and early clinical evaluation of a phase I trial (presentation). Soria, J-C. et al. European CanCer Organization 2005 Annual Meeting
Development of potent and selective inhibitors of FLT-3 kinase with good pharmacokinetic profiles (poster). Grotzfeld, R.M. et al. American Cancer Society Annual Meeting 2005
Discovery of potent and specific FLT-3 kinase inhibitors (poster). Patel, H.K. et al. American Cancer Society Annual Meeting 2005